Squamous cell and urothelial carcinomas in an ileal neobladder

Fujimoto, Takeru; Sakamoto, Hiromasa; Sakurai, Takaki; Kanai, Kasumi; Imai, Kazuto; Aoyama, Teruyoshi

doi:10.1002/iju5.12414

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cases of malignancy in urinary diversions involving the ileum are extremely uncommon, with a limited number of well‐documented cases published in English literature, the majority of which are individual case reports and a few case series (Tables 2 and 3). 4,7,9–43 Urinary bladder augmentation poses a greater risk of late uroenteric cancer compared to the ileal conduit or ileal replacement of the ureter 2,4,7 . New primary malignancies that develop after bladder augmentation are typically found near the ileovesical anastomosis 2 .…”

Section: Discussionmentioning

confidence: 99%

Carcinoma arising in ileal conduit or orthotopic ileal neobladder reconstruction: A 20‐year single institute experience

Collins,

Yocum,

Idrees

et al. 2024

Histopathology

View full text Add to dashboard Cite

ContextCarcinomas found in urinary diversion specimens are uncommon, particularly new primary tumours. New primary tumours primarily occur when the large intestine is utilised, whereas the occurrence is infrequent with the use of the ileum. These tumours include both the recurrence of primary malignancy or the development of a new primary malignancy originating from the small intestine.DesignA search was performed within the pathology laboratory system to identify cases of malignancies involving ileal conduit/reconstruction from 2002 to 2022. Data on demographics, clinical details, pathology and management was recorded.ResultsA total of 13 male patients, with a mean age of 67 years (range = 49–81 years) were included in the study. The initial procedure performed included cystoprostatectomy (n = 10, including one case with right nephroureterectomy) and cystectomy (n = 3, including one case for bladder exstrophy) for initial diagnoses including urothelial carcinoma (n = 11; conventional, 6; sarcomatoid, 1; glandular 1; plasmacytoid, 1; micropapillary, 2) and adenocarcinoma (n = 1). The initial management included radical surgery with neoadjuvant chemotherapy/immunotherapy (n = 1), adjuvant chemotherapy (n = 3), intravesical adjuvant BCG (n = 2) and intravesical adjuvant chemotherapy (n = 1). Malignancies in ileal conduit or orthotopic ileal neobladder included recurrent urothelial carcinoma (n = 10) and new secondary adenocarcinomas (n = 3), which developed as early as 3 months (usually recurrence) and up to 13, 33 and 45 years (new primary malignancy) following primary resection.ConclusionsUtilising the ileum as conduit/neobladder presents a viable alternative for urinary diversion with a reduced malignancy risk compared to using a segment of the large intestine. However, there remains a potential for malignancy, either tumour recurrence or a new primary malignancy. In our study, tumour recurrence occurred up to 4 years following the initial diagnosis and the development of a new primary malignancy occurred up to 45 years after the initial diagnosis. Consequently, it is crucial to prioritise long‐term follow‐up for these patients undergoing this procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

Carcinoma arising in ileal conduit or orthotopic ileal neobladder reconstruction: A 20‐year single institute experience

Collins,

Yocum,

Idrees

et al. 2024

Histopathology

View full text Add to dashboard Cite

show abstract

Squamous cell and urothelial carcinomas in an ileal neobladder

Fujimoto¹,

Sakamoto²,

Sakurai

et al. 2022

IJU Case Reports

Self Cite

View full text Add to dashboard Cite

show abstract

Ein äußerst seltener Fall von multiplen Rezidiven eines Urothelzellkarzinoms in einer ilealen Neoblase: Fallbericht und Literaturübersicht

Clauser,

Palermo,

Palermo

et al. 2024

Aktuelle Urol

View full text Add to dashboard Cite

Zusammenfassung In bis zu 18% tritt nach kurativer radikaler Zystektomie wegen eines Urothelkarzinoms ein Rezidiv auf. Zumeist manifestieren sich die Rezidive in den regionären Lymphknoten oder im verbliebenen oberen oder unteren Harntrakt. Extrem selten tritt ein Rezidiv in einer Neoblase auf, zumal es sich um ein anderes embryonales Keimblatt handelt. Wir berichten über einen Fall, bei dem 10 Jahre nach der Zystoprostatektomie multiple Urothelkarzinomrezidive nur in der Neoblase auftraten. Daraufhin wurde die Neoblase entfernt und ein Sigma-Conduit angelegt. Trotzdem trat 6 Monate später eine generalisierte Metastasierung auf, woran der Patient wenig später verstarb. Zurzeit gibt es aufgrund der Seltenheit dieses Krankheitsbilds keine Behandlungsrichtlinien. Wir schildern unsere Erfahrungen und geben eine Literaturübersicht.

show abstract

Squamous cell and urothelial carcinomas in an ileal neobladder

Abstract: IHC = immunohistochemical SCC = squamous cell carcinoma TURBT = transurethral resection of a bladder tumor UC = urothelial carcinoma

Cited by 3 publications

References 17 publications

Carcinoma arising in ileal conduit or orthotopic ileal neobladder reconstruction: A 20‐year single institute experience

Carcinoma arising in ileal conduit or orthotopic ileal neobladder reconstruction: A 20‐year single institute experience

Squamous cell and urothelial carcinomas in an ileal neobladder

Ein äußerst seltener Fall von multiplen Rezidiven eines Urothelzellkarzinoms in einer ilealen Neoblase: Fallbericht und Literaturübersicht

Contact Info

Product

Resources

About